Search

Your search keyword '"Zhou, Huafeng"' showing total 249 results

Search Constraints

Start Over You searched for: Author "Zhou, Huafeng" Remove constraint Author: "Zhou, Huafeng"
249 results on '"Zhou, Huafeng"'

Search Results

53. Characterisation and Skin Distribution of Lecithin-Based Coenzyme Q10-Loaded Lipid Nanocapsules

54. Preparation and Characterization of a Lecithin Nanoemulsion as a Topical Delivery System

60. A Power Market Nodal Price Forecasting Based on Historical Electricity Price and Unified Dispatch Load

64. Peak-shift Optimization Model and Pricing Strategies of Power Trading System in Bay Area

66. Utilization of polyacrylamide-thickening agent and aluminum sulfate liquid accelerator for improving early strength of Portland cement.

68. Obeticholic acid demonstrates sustained improvements at month 24 in transaminases and non-invasive markers of fibrosis: results of a post hoc analysis from the interim analysis of the REGENERATE study

71. On-line PMU-based transmission line parameter identification

76. Relationship of JAK2V617F Allelic Burden (AB) to Demographics, Disease Characteristics, and Response to Therapy in Persist-1, a Randomized Phase III Study of Pacritinib (PAC) Versus Best Available Therapy (BAT) in Patients (pts) with Primary and Secondary Myelofibrosis (MF)

77. Calculating sequence impedances of transmission line using PMU measurements

78. Influence of diamond-like carbon coatings and micro-texturing on friction and wear of seal interfaces: Experiment and simulation study

79. Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia.

80. Outcomes in patients with myelofibrosis and RBC-transfusion dependence in the phase III PERSIST-1 study of pacritinib vs. best available therapy.

84. Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia.

85. Outcomes in patients with myelofibrosis and RBC-transfusion dependence in the phase III PERSIST-1 study of pacritinib vs. best available therapy.

89. Safety analysis by UGT1A1 status of TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI).

90. Research and development of Operation Smart System in CSG

91. Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction

100. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial

Catalog

Books, media, physical & digital resources